Lumasiran in Hyperoxalaemic Patients on Haemodialysis

NCT06225544 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Haemodialysis
Chronic Kidney Disease Requiring Chronic Dialysis
Cardiovascular Disease
Cardiovascular Risk Factor
Hyperoxalemia

Interventions

DRUG: Lumasiran
DRUG: 0.9% Sodium Chloride (placebo)

Sponsor

Charite University, Berlin, Germany

Collaborators

[object Object]